Recent pharmacological advances in the management of gout

被引：15
作者：
Davies, Kristen [1 ]
Bukhari, Marwan A. S. [1 ,2 ]
机构：
[1] Univ Lancaster, Fac Hlth & Med, Lancaster, England
[2] Univ Hosp Morecambe Bay NHS Fdn Trust, Royal Lancaster Infirm, Dept Rheumatol, Lancaster, England
来源：
RHEUMATOLOGY | 2018年 / 57卷 / 06期
关键词：
gout; management; EULAR; IL-1; allopurinol; canakinumab; anakinra; febuxostat; pharmacology; lesinurad; DOUBLE-BLIND; TOPHACEOUS GOUT; URIC-ACID; LOWERING THERAPY; COST-EFFECTIVENESS; FLARE PREVENTION; RENAL-FUNCTION; PHASE-III; ALLOPURINOL; FEBUXOSTAT;
D O I：
10.1093/rheumatology/kex343
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
Gout is the most common cause of inflammatory arthritis worldwide, and reports show that despite availability of therapies, management is still suboptimal. The new EULAR 2016 recommendations for the treatment of gout highlight the huge development in gout therapies, and the number of drugs being trialled only continues to increase. A clinical review of the evidence that underlies the recommendations from EULAR can reveal possible gaps in the literature and avenues for future research into gout therapies.
引用
收藏
页码：951 / 958
页数：8
相关论文
共 75 条
[1]   Identifying Patient Candidates for IL-1 Inhibition: Lessons From Real-World Cases [J].
Avram, Annalina ;
Duarte, Catia ;
Santos, Maria Jose ;
Papagoras, Charalampos ;
Ritis, Konstantinos ;
Scarpioni, Roberto ;
Schmidt, Wolfgang A. ;
Skendros, Panagiotis .
JOINT BONE SPINE, 2015, 82 :ES17-ES29
[2]   Inhibiting the Inflammasome: A Chemical Perspective [J].
Baldwin, Alex G. ;
Brough, David ;
Freeman, Sally .
JOURNAL OF MEDICINAL CHEMISTRY, 2016, 59 (05) :1691-1710
[3]   Resolution of gouty tophi after twelve weeks of pegloticase treatment [J].
Baraf, Herbert S. B. ;
Matsumoto, Alan K. ;
Maroli, Allan N. ;
Waltrip, Royce W., II .
ARTHRITIS AND RHEUMATISM, 2008, 58 (11) :3632-3634
[4]   Infusion-Related Reactions With Pegloticase, a Recombinant Uricase for the Treatment of Chronic Gout Refractory to Conventional Therapy [J].
Baraf, Herbert S. B. ;
Yood, Robert A. ;
Ottery, Faith D. ;
Sundy, John S. ;
Becker, Michael A. .
JCR-JOURNAL OF CLINICAL RHEUMATOLOGY, 2014, 20 (08) :427-432
[5]   Tophus burden reduction with pegloticase: results from phase 3 randomized trials and open-label extension in patients with chronic gout refractory to conventional therapy [J].
Baraf, Herbert S. B. ;
Becker, Michael A. ;
Gutierrez-Urena, Sergio R. ;
Treadwell, Edward L. ;
Vazquez-Mellado, Janitzia ;
Rehrig, Claudia D. ;
Ottery, Faith D. ;
Sundy, John S. ;
Yood, Robert A. .
ARTHRITIS RESEARCH & THERAPY, 2013, 15 (05)
[6]   Lesinurad in combination with allopurinol: a randomised, double-blind, placebo-controlled study in patients with gout with inadequate response to standard of care (the multinational CLEAR 2 study) [J].
Bardin, Thomas ;
Keenan, Robert T. ;
Khanna, Puja P. ;
Kopicko, Jeff ;
Fung, Maple ;
Bhakta, Nihar ;
Adler, Scott ;
Storgard, Chris ;
Baumgartner, Scott ;
So, Alexander .
ANNALS OF THE RHEUMATIC DISEASES, 2017, 76 (05) :811-820
[7]   Cost-effectiveness of febuxostat in chronic gout [J].
Beard, Stephen M. ;
von Scheele, Birgitta G. ;
Nuki, George ;
Pearson, Isobel V. .
EUROPEAN JOURNAL OF HEALTH ECONOMICS, 2014, 15 (05) :453-463
[8]   Febuxostat compared with allopurinol in patients with hyperuricemia and gout [J].
Becker, MA ;
Schumacher, HR ;
Wortmann, RL ;
MacDonald, PA ;
Eustace, D ;
Palo, WA ;
Streit, J ;
Joseph-Ridge, N .
NEW ENGLAND JOURNAL OF MEDICINE, 2005, 353 (23) :2450-2461
[9]   The urate-lowering efficacy and safety of febuxostat in the treatment of the hyperuricemia of gout: the CONFIRMS trial [J].
Becker, Michael A. ;
Schumacher, H. Ralph ;
Espinoza, Luis R. ;
Wells, Alvin F. ;
MacDonald, Patricia ;
Lloyd, Eric ;
Lademacher, Christopher .
ARTHRITIS RESEARCH & THERAPY, 2010, 12 (02)
[10]   Clinical Efficacy and Safety of Successful Longterm Urate Lowering with Febuxostat or Allopurinol in Subjects with Gout [J].
Becker, Michael A. ;
Schumacher, H. Ralph ;
MacDonald, Patricia A. ;
Lloyd, Eric ;
Lademacher, Christopher .
JOURNAL OF RHEUMATOLOGY, 2009, 36 (06) :1273-1282
12345678